Verinata Health Announces New Corporate Headquarters and Expanded Laboratory Operations
REDWOOD CITY, Calif., Dec. 7, 2011 /PRNewswire/ — Verinata Health, Inc., a privately-held company dedicated to maternal and fetal health, today announced the relocation of its corporate headquarters and laboratory operations to 800 Saginaw Drive, Redwood City, California.
“Our move to a much larger and state-of-the art facility is a demonstration of our commitment to appropriately prepare for the growth and expansion expected with the launch of our first product,” said Caren L. Mason, Chief Executive Officer of Verinata. “We have designed a clinical laboratory with initial capacity of over 150,000 tests annually. In addition, we have expanded our R&D laboratory substantially, with further expansion opportunities available for both clinical and research space. Our corporate headquarters is also designed to uniquely and distinctively support our physician, patient, and payer support teams to provide the education, training and support services for our laboratory developed test.”
Ms. Mason continued, “We are pleased to report that our non-invasive prenatal test for multiple chromosomal abnormalities remains on track for commercial launch in the first quarter of 2012.”
Verinata Health, Inc.
Verinata is driven by a sole, extraordinary purpose – maternal and fetal health. Our initial focus is to develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities using our proprietary technologies. We aim to reduce the anxiety associated with today’s multi-step process, the unacceptable false-positive rates, the non-specific and sometimes confusing results of current prenatal screening methods, as well as the risk of current invasive procedures. In support of national guidelines recommending first trimester aneuploidy risk assessment, we believe women who desire such an assessment should be offered a single blood draw test with a definitive result. Verinata is conducting a prospective, blinded pivotal study to clinically validate the sensitivity and specificity of its first prenatal test on a large scale with results of the study expected in 2011. For more information about Verinata, please go to www.verinata.com.
SOURCE Verinata Health, Inc.